Market capitalization | $53.41m |
Enterprise Value | $38.41m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 3.57 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-8.00m |
Free Cash Flow (TTM) Free Cash Flow | $-6.65m |
Cash position | $15.00m |
As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.
1 Analyst has issued a forecast Anebulo Pharmaceuticals Inc:
1 Analyst has issued a forecast Anebulo Pharmaceuticals Inc:
Dec '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -8 -8 |
25%
25%
|
EBIT (Operating Income) EBIT | -8 -8 |
25%
25%
|
Net Profit | -7.67 -7.67 |
27%
27%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Anebulo Pharmaceuticals, Inc. engages in the provision of pharmaceutical services. The firm product candidate is ANEB-001, a potent, small molecule cannabinoid receptor antagonist, designed to address the unmet medical need for a specific antidote for cannabinoid overdose. The company was founded by Lawyer Joseph F on April 23, 2020 and is headquartered in Lakeway, TX.
Head office | United States |
CEO | Richard Cunningham |
Employees | 3 |
Founded | 2020 |
Website | www.anebulo.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.